108 related articles for article (PubMed ID: 2229455)
1. Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease.
Puri SK; Ho I; Hsu R; Lassman HB
J Clin Pharmacol; 1990 Oct; 30(10):948-55. PubMed ID: 2229455
[TBL] [Abstract][Full Text] [Related]
2. Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's disease.
Cutler NR; Sramek JJ; Murphy MF; Nash RJ
Ann Pharmacother; 1992 Sep; 26(9):1118-22. PubMed ID: 1421679
[TBL] [Abstract][Full Text] [Related]
3. The effect of food on the bioavailability of velnacrine (HP 029) in healthy elderly men: a potential Alzheimer agent.
Puri SK; Hsu RS; Ho I; Lassman HB
J Clin Pharmacol; 1989 Oct; 29(10):956-60. PubMed ID: 2592587
[TBL] [Abstract][Full Text] [Related]
4. Single dose safety, tolerance, and pharmacokinetics of HP 029 in healthy young men: a potential Alzheimer agent.
Puri SK; Hsu RS; Ho I; Lassman HB
J Clin Pharmacol; 1989 Mar; 29(3):278-84. PubMed ID: 2723116
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's patients should be included in phase I clinical trials to evaluate compounds for Alzheimer's disease.
Cutler NR; Sramek JJ; Murphy MF; Nash RJ
J Geriatr Psychiatry Neurol; 1992; 5(4):192-4. PubMed ID: 1418362
[TBL] [Abstract][Full Text] [Related]
6. Velnacrine for Alzheimer's disease.
Birks J; Wilcock GG
Cochrane Database Syst Rev; 2004; (2):CD004748. PubMed ID: 15106259
[TBL] [Abstract][Full Text] [Related]
7. Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings.
Cutler NR; Murphy MF; Nash RJ; Prior PL; De Luna DM
J Clin Pharmacol; 1990 Jun; 30(6):556-61. PubMed ID: 2355106
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease.
Murphy MF; Hardiman ST; Nash RJ; Huff FJ; Demkovich JJ; Dobson C; Knappe UE
Ann N Y Acad Sci; 1991; 640():253-62. PubMed ID: 1776747
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Antuono PG
Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
[TBL] [Abstract][Full Text] [Related]
10. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
Zemlan FP
J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
[TBL] [Abstract][Full Text] [Related]
11. Variability in the plasma protein binding of velnacrine (1-hydroxy tacrine hydrochloride). A potential agent for Alzheimer's disease.
Wood DM; Ford JM; Roberts CJ
Eur J Clin Pharmacol; 1996; 50(1-2):115-9. PubMed ID: 8739821
[TBL] [Abstract][Full Text] [Related]
12. Double-blind placebo-controlled study of velnacrine in Alzheimer's disease.
Zemlan FP; Keys M; Richter RW; Strub RL
Life Sci; 1996; 58(21):1823-32. PubMed ID: 8637408
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers.
Jones A; Wang-Smith L; Pham T; Laliberte K
J Cardiovasc Pharmacol; 2014 Mar; 63(3):227-32. PubMed ID: 24603117
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study.
Barbhaiya RH; Marathe PH; Greene DS; Mayol RF; Shukla UA; Gammans RR; Pittman KA; Robinson D
J Clin Pharmacol; 1995 Oct; 35(10):974-84. PubMed ID: 8568015
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
[TBL] [Abstract][Full Text] [Related]
16. Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease.
Cutler NR; Sedman AJ; Prior P; Underwood BA; Selen A; Balogh L; Kinkel AW; Gracon SI; Gamzu ER
Psychopharmacol Bull; 1990; 26(2):231-4. PubMed ID: 2236461
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic and early clinical studies with velnacrine.
Siegfried KR
Acta Neurol Scand Suppl; 1993; 149():26-8. PubMed ID: 8128834
[TBL] [Abstract][Full Text] [Related]
19. Clinical trials with velnacrine: (PROPP) the physician reference of predicted probabilities--a statistical model for the estimation of hepatotoxicity risk with velnacrine maleate.
Hardiman S; Miller K; Murphy M
Acta Neurol Scand Suppl; 1993; 149():46-52. PubMed ID: 8128839
[TBL] [Abstract][Full Text] [Related]
20. Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age.
Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
Clin Ther; 2016 Jan; 38(1):39-52. PubMed ID: 26581327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
